ADVERTISEMENT
ADVERTISEMENT
Elephas Biosciences appoints Premal Patel as CMO
The move strengthens clinical leadership ahead of the company’s commercial launch of the live tumor immunology platform.
-
1759163132.png)
Anushka Pathak - Wed, 14, Jan 2026
- 16:20 EST
- 20
Premal Patel, the new chief medical officer of Elephas Biosciences / Courtesy: LinkedIn
Wisconsin-based biotechnology company Elephas Biosciences has appointed Premal H. Patel as the chief medical officer.
The move comes as the company advances toward the commercial launch of its live tumor immunology platform and records progress, including a peer-reviewed publication in the 'Journal of Translational Medicine,' the closing of a US$42 million financing round, and the expansion of commercial partnerships with global collaborators.
ALSO READ: Arpit Davé appointed BioMarin Executive VP
Elephas has developed the Elephas Live platform, an ex vivo technology that evaluates how live tumor biopsies respond to immunotherapies. The platform preserves the native tumor microenvironment from a core needle biopsy and accounts for tumor heterogeneity, enabling real-time assessment of immune responses.
The company aims to generate predictive insights into immunotherapy effectiveness before treatment begins, addressing the low response rates seen across current therapies.
"It's an exciting and pivotal moment for Elephas," Patel said. "By using a patient's own live tumor to generate clinically actionable insights, Elephas could transform how treatment decisions are made. This approach directly addresses a major unmet need in metastatic cancer, helping to identify the most effective therapy for each patient."
Elephas founder and chief executive officer Maneesh Arora said the appointment strengthens the company’s ability to translate its technology into clinical impact. "Our strength lies in our people and their commitment to developing and delivering a transformative functional solution for cancer researchers and patients," Arora said.
Patel is a physician-scientist with more than 20 years of experience across oncology drug development and clinical strategy. He previously served as chief executive officer of Cellinfinity Bio and held senior leadership roles at several biopharmaceutical companies, where he guided clinical programs through advanced development stages.
Cancer continues to be a leading cause of death globally, with patient numbers projected to increase sharply by 2060, highlighting the need for more accurate tools to guide treatment decisions.
Discover more at New India Abroad.
Related
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login